[go: up one dir, main page]

TR200400815T3 - AtorvastatinÁyarı@kalsiyumunÁyeniÁkristalÁformlarıÁveÁbunlarınÁhazırlanmasıÁiçinÁişlemlerÁayrıcaÁdiğerÁformlarınÁhazırlanmasıÁiçinÁyeniÁişlemler - Google Patents

AtorvastatinÁyarı@kalsiyumunÁyeniÁkristalÁformlarıÁveÁbunlarınÁhazırlanmasıÁiçinÁişlemlerÁayrıcaÁdiğerÁformlarınÁhazırlanmasıÁiçinÁyeniÁişlemler

Info

Publication number
TR200400815T3
TR200400815T3 TR2004/00815T TR200400815T TR200400815T3 TR 200400815 T3 TR200400815 T3 TR 200400815T3 TR 2004/00815 T TR2004/00815 T TR 2004/00815T TR 200400815 T TR200400815 T TR 200400815T TR 200400815 T3 TR200400815 T3 TR 200400815T3
Authority
TR
Turkey
Prior art keywords
atorvastatin
forms
atorvastatináyar
preparation
new
Prior art date
Application number
TR2004/00815T
Other languages
English (en)
Inventor
Judith�Aronhime
Ramy�Lidor@Hadas
Valerie�Niddam
Revital�Lifshitz
Eti�Ishai
Guy�Sambursky
Original Assignee
Teva�Pharmaceutical�Industries�Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27540285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200400815(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva�Pharmaceutical�Industries�Ltd filed Critical Teva�Pharmaceutical�Industries�Ltd
Publication of TR200400815T3 publication Critical patent/TR200400815T3/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Bu bulus, VI, VIII., IX., X., XI. ve XII. formlar olarak adlandirilan yeni atorvastatin formlarini ve bunlarin hazirlanmasi için yeni islemleri ve ayrica atorvastatinin I., II., IV., V. formlarinin ve sekilsiz atorvastatinin hazirlanmasi için islemleri saglar.
TR2004/00815T 2000-11-30 2001-11-29 AtorvastatinÁyarı@kalsiyumunÁyeniÁkristalÁformlarıÁveÁbunlarınÁhazırlanmasıÁiçinÁişlemlerÁayrıcaÁdiğerÁformlarınÁhazırlanmasıÁiçinÁyeniÁişlemler TR200400815T3 (tr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25007200P 2000-11-30 2000-11-30
US26789701P 2001-02-09 2001-02-09
US28187201P 2001-04-05 2001-04-05
US31214401P 2001-08-13 2001-08-13
US32652901P 2001-10-01 2001-10-01

Publications (1)

Publication Number Publication Date
TR200400815T3 true TR200400815T3 (tr) 2004-07-21

Family

ID=27540285

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2004/00815T TR200400815T3 (tr) 2000-11-30 2001-11-29 AtorvastatinÁyarı@kalsiyumunÁyeniÁkristalÁformlarıÁveÁbunlarınÁhazırlanmasıÁiçinÁişlemlerÁayrıcaÁdiğerÁformlarınÁhazırlanmasıÁiçinÁyeniÁişlemler

Country Status (23)

Country Link
US (15) US20020183378A1 (tr)
EP (5) EP2192112B1 (tr)
JP (2) JP2004514694A (tr)
KR (1) KR100765871B1 (tr)
CN (1) CN1489463A (tr)
AU (1) AU2002217927A1 (tr)
BG (1) BG107856A (tr)
BR (1) BR0115892A (tr)
CA (3) CA2689915A1 (tr)
CZ (1) CZ20031766A3 (tr)
DE (1) DE01998348T1 (tr)
ES (2) ES2215495T1 (tr)
HR (2) HRP20030523A2 (tr)
HU (1) HUP0600538A3 (tr)
IL (2) IL156055A0 (tr)
IS (1) IS6829A (tr)
MX (1) MXPA03004844A (tr)
NO (1) NO20032425L (tr)
PL (1) PL363228A1 (tr)
SK (1) SK8062003A3 (tr)
TR (1) TR200400815T3 (tr)
WO (1) WO2002043732A1 (tr)
YU (1) YU42803A (tr)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE36268E (en) * 1988-03-15 1999-08-17 Boehringer Mannheim Corporation Method and apparatus for amperometric diagnostic analysis
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
JP2004513956A (ja) * 2000-11-03 2004-05-13 テバ　ファーマシューティカル　インダストリーズ　リミティド アトルバスタチンヘミカルシウムｖｉｉ型
SK7212003A3 (en) * 2000-11-16 2004-03-02 Teva Pharma Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy- 5-(1-methylethyl)-3-fenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1- heptanoic acid esters with calcium hydroxide
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
DE60137364D1 (de) 2000-12-27 2009-02-26 Teva Pharma Kristalline formen von atorvastatin
CN1524073A (zh) * 2001-06-29 2004-08-25 ����-�����ع�˾ ′R-(R*,R*)-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-(苯基氨基）羰基-1H-吡咯-1-庚酸钙盐（2∶1）（阿托伐他汀）
US7074818B2 (en) 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
EP2292600A1 (en) * 2001-07-30 2011-03-09 Dr. Reddy's Laboratories Ltd. Crystaline forms VI and VII of atorvastatin calcium
MXPA04001451A (es) * 2001-08-16 2005-02-17 Teva Pharma Procesos para preparar formas de sal de calcio de estatinas.
CZ296967B6 (cs) * 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
DE03713610T1 (de) * 2002-02-15 2005-10-20 Teva Pharma Neue kristallformen von atorvastatin-hemicalcium und verfahren zu deren herstellung, sowie neue verfahren zur herstellung der formen i, viii und ix von atorvastatin-hemicalcium
HRP20040767A2 (en) 2002-02-19 2004-12-31 Teva Pharma Desolvating solvates of atorvastatin hemi-calcium
AU2002356423A1 (en) * 2002-05-28 2003-12-12 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
EP1562583A1 (en) * 2002-09-03 2005-08-17 Morepen Laboratories Ltd. Atorvastatin calcium form vi or hydrates thereof
WO2004050618A2 (en) * 2002-11-28 2004-06-17 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
EP1424324A1 (en) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
CA2526730A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
AU2004317570B2 (en) 2004-03-17 2011-01-06 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
US7875731B2 (en) 2004-05-05 2011-01-25 Pfizer Inc. Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid
MXPA06013672A (es) * 2004-05-24 2007-02-13 Warner Lambert Co Formas salinas del acido [r-(r*, r*)]-2-(4- fluorofenil)-??, d-dihidroxi-5 -(1-metiletil)-3- fenil-4 -[(fenilamino)carbonil] -1h-pirrol -1-heptanoico._.
EP1771455B1 (en) * 2004-07-16 2016-05-11 LEK Pharmaceuticals d.d. Oxidative degradation products of atorvastatin calcium
JP2008506764A (ja) 2004-07-20 2008-03-06 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態
WO2006012499A2 (en) * 2004-07-22 2006-02-02 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation
TW200825092A (en) * 2004-09-28 2008-06-16 Teva Pharma A method for reducing the level of AED in atorvastatin calcium sample
KR20070106680A (ko) * 2004-09-30 2007-11-05 닥터 레디스 레보러터리즈 리미티드 비정질 아토르바스타틴 칼슘
ES2272206T1 (es) * 2004-10-18 2007-05-01 Teva Pharmaceutical Industries Ltd. Procedimiento para la preparacion de la atorvastatina hemicalcica amorfa por disolucion de la sal en un disolvente organico que es una mezcla de un alcohol, y una cetona y/o un ester y eliminacion del disolvente.
MX2007004722A (es) 2004-10-28 2007-06-15 Warner Lambert Co Procedimiento para formar atorvastatina amorfa.
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
AU2005305460B2 (en) * 2004-11-22 2011-04-21 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
PL1698630T3 (pl) * 2005-03-03 2014-12-31 Alfasigma Spa Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych
SK288276B6 (sk) * 2005-04-08 2015-06-02 Egis Gyógyszergyár, Nyilvánosan Működő Részvénytársaság Spôsob prípravy kryštalickej polymorfnej formy hemivápenatej soli atorvastatínu
US20070032665A1 (en) * 2005-08-04 2007-02-08 Srinivasulu Gudipati Preparation of atorvastatin calcium form i
ES2270722B1 (es) * 2005-09-15 2008-03-01 Ercros Industrial, S.A. Procedimiento para la obtencion de atorvastatina calcica amorfa.
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
BRPI0618379A2 (pt) 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
ATE466840T1 (de) 2005-11-21 2010-05-15 Warner Lambert Co Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium
EP1808162A1 (en) 2005-11-21 2007-07-18 Teva Pharmaceutical Industries Ltd. Atorvastatin pharmaceutical formulation
EP1923057A1 (en) 2005-11-21 2008-05-21 Teva Pharmaceutical Industries Ltd Atorvastatin pharmaceutical formulation
TW200745026A (en) 2005-12-13 2007-12-16 Teva Pharma Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
JP2007246514A (ja) * 2006-02-14 2007-09-27 Toyama Chem Co Ltd ピペラシリンナトリウムの新規な結晶
US20090240064A1 (en) * 2006-02-22 2009-09-24 Venkata Panakala Rao Gogulapati Crystalline form of atorvastatin hemi-calcium
CA2640573A1 (en) * 2006-03-01 2007-09-13 Michael Pinchasov Process for preparing a crystalline form of atorvastatin hemi-calcium
US20070265456A1 (en) * 2006-05-09 2007-11-15 Judith Aronhime Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CN100406438C (zh) * 2006-06-30 2008-07-30 浙江新东港药业股份有限公司 一种无定型阿伐他汀钙的制备方法
JP2009543773A (ja) * 2006-07-14 2009-12-10 ランバクシー ラボラトリーズ リミテッド ＨＭＧ−ＣｏＡレダクターゼ阻害剤の多形体及びその使用
EP2081554A2 (en) * 2006-09-27 2009-07-29 Dr. Reddy's Laboratories Ltd. Atorvastatin pharmaceutical compositions
WO2008053312A2 (en) * 2006-11-02 2008-05-08 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its intermediate
US7834195B2 (en) * 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
US20100063273A1 (en) * 2007-01-31 2010-03-11 Toyama Chemical Co., Ltd Novel crystal of piperacillin sodium
CN101657419A (zh) * 2007-03-02 2010-02-24 东亚制药株式会社 吡咯基庚酸衍生物的新晶型
WO2008129562A2 (en) * 2007-04-20 2008-10-30 Morepen Laboratories Limited An improved process for the preparation of stable amorphous atorvastatin hemi calcium and their salts thereof
WO2009016358A2 (en) * 2007-07-27 2009-02-05 Cipla Limited Pharmaceutical compositions and process for making them
WO2009082362A1 (en) * 2007-11-05 2009-07-02 Ulkar Kimya San. Ve Tic. A.S. A method for producing statins in pure form
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
CN101538237B (zh) * 2008-05-30 2011-04-06 天津和美生物技术有限公司 阿伐他汀半钙盐丁酮共结晶物、其制备和作为HMG-CoA酶抑制剂的应用
US8685173B2 (en) 2008-07-17 2014-04-01 Delaval Holding Ab Method of cleaning food and beverage manufacturing and handling equipment
WO2011028309A1 (en) 2009-09-04 2011-03-10 University Of Toledo PROCESSES FOR PRODUCING OPTICALLY PURE β-LACTONES FROM ALDEHYDES AND COMPOSITIONS PRODUCED THEREBY
US11473032B2 (en) 2010-02-02 2022-10-18 Fuchs Petrolub Se Constant velocity joint having a boot
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
CN102766136A (zh) * 2012-08-07 2012-11-07 浙江宏元药业有限公司 一种制备阿托伐他汀钙中间体的方法
PE20160945A1 (es) 2013-11-15 2016-09-26 Akebia Therapeutics Inc Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acetico, composiciones, y usos de las mismas
CN103641764B (zh) * 2013-11-25 2015-12-02 北京三泉医药技术有限公司 调节血脂的药物组合物
CN104945300B (zh) * 2015-06-17 2017-05-10 北京嘉林药业股份有限公司 一种ⅰ型阿托伐他汀钙的纯化方法
CN104983690A (zh) * 2015-08-18 2015-10-21 青岛蓝盛洋医药生物科技有限责任公司 一种治疗冠心病的药物阿托伐他汀钙组合物干混悬剂
EP3272336A1 (de) * 2016-07-19 2018-01-24 Stada Arzneimittel Ag Atorvastatin-zusammensetzung
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US115709A (en) * 1871-06-06 Improvement in curriers slickers
US99224A (en) * 1870-01-25 Improvement in pocket-sates for friction-matches
US2598627A (en) * 1949-10-11 1952-05-27 Robert Gair Co Inc Folding carton
US4137322A (en) * 1976-11-02 1979-01-30 Sankyo Company Limited ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
CA2150372C (en) * 1993-01-19 2002-08-20 Nancy L. Mills Stable oral ci-981 formulation and process of preparing same
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
DE4411536A1 (de) * 1994-04-02 1995-10-05 Cassella Ag Wasserquellbare hydrophile Polymere
HRP960312B1 (en) 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
DE69634054T2 (de) * 1995-07-17 2005-12-08 Warner-Lambert Co. Kristalline (R-(R*, R*))-2-(4-Fluorophenyl)-β, δ-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-((Phenylamino)Carbonyl)-1H-Pyrrol-1-Heptancarbonsäure Hemi Calcium Salz (Atorvastatin)
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US6065729A (en) * 1998-01-28 2000-05-23 Prince Corporation Slide-out container holder
US5959156A (en) 1998-11-12 1999-09-28 Bp Amoco Corporation Preparation of polyoxymethylene dimethyl ethers by catalytic conversion of dimethyl ether with formaldehyde formed by oxy-dehydrogenation of dimethyl ether
IN191236B (tr) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
HU226640B1 (en) * 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
KR20020063190A (ko) * 1999-11-17 2002-08-01 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 칼슘의 다형태
US7411075B1 (en) * 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
EP1584616A1 (en) 1999-12-17 2005-10-12 Pfizer Science and Technology Ireland Limited Industrial process for the production of crystalline atorvastatin trihydrate hemi calcium salt
DE60026737T2 (de) 1999-12-17 2006-09-21 Pfizer Science And Technology Ireland Ltd., Dun Laoghaire Verfahren zur herstellung von kristallin atorvastin kalcium
JP2004513956A (ja) * 2000-11-03 2004-05-13 テバ　ファーマシューティカル　インダストリーズ　リミティド アトルバスタチンヘミカルシウムｖｉｉ型
SK7212003A3 (en) * 2000-11-16 2004-03-02 Teva Pharma Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy- 5-(1-methylethyl)-3-fenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1- heptanoic acid esters with calcium hydroxide
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
DE60137364D1 (de) * 2000-12-27 2009-02-26 Teva Pharma Kristalline formen von atorvastatin
US6476235B2 (en) 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
WO2002057228A1 (en) 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (tr) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
CN1524073A (zh) * 2001-06-29 2004-08-25 ����-�����ع�˾ ′R-(R*,R*)-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-(苯基氨基）羰基-1H-吡咯-1-庚酸钙盐（2∶1）（阿托伐他汀）
US7074818B2 (en) * 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
EP2292600A1 (en) 2001-07-30 2011-03-09 Dr. Reddy's Laboratories Ltd. Crystaline forms VI and VII of atorvastatin calcium
MXPA04001451A (es) * 2001-08-16 2005-02-17 Teva Pharma Procesos para preparar formas de sal de calcio de estatinas.
EP1572638A4 (en) 2001-08-31 2010-05-05 Morepen Lab Ltd IMPROVED METHOD FOR THE PRODUCTION OF AMORPHIC ATORVASTATIN CALCIUM SALT (2: 1)
EP1474167A4 (en) 2001-11-30 2006-03-22 Univ Maryland NOVEL PROTEINS IN ENTERO-AGREGATIVE ESCHERICHIA COLI (EAEC) USED FOR THE DIAGNOSIS AND THERAPY OF EAEC INFECTIONS
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
DE03713610T1 (de) 2002-02-15 2005-10-20 Teva Pharma Neue kristallformen von atorvastatin-hemicalcium und verfahren zu deren herstellung, sowie neue verfahren zur herstellung der formen i, viii und ix von atorvastatin-hemicalcium
HRP20040767A2 (en) 2002-02-19 2004-12-31 Teva Pharma Desolvating solvates of atorvastatin hemi-calcium
WO2003083638A2 (en) 2002-03-28 2003-10-09 Emc Corporation Data storage system
AU2002356423A1 (en) * 2002-05-28 2003-12-12 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
EP1562583A1 (en) 2002-09-03 2005-08-17 Morepen Laboratories Ltd. Atorvastatin calcium form vi or hydrates thereof
SI21302A (sl) 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
WO2004050618A2 (en) 2002-11-28 2004-06-17 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
EP1424324A1 (en) 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
US20040242670A1 (en) * 2003-06-02 2004-12-02 Sonny Sebastian Process for preparation of amorphous atorvastatin calcium
WO2006012499A2 (en) * 2004-07-22 2006-02-02 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation
ES2272206T1 (es) * 2004-10-18 2007-05-01 Teva Pharmaceutical Industries Ltd. Procedimiento para la preparacion de la atorvastatina hemicalcica amorfa por disolucion de la sal en un disolvente organico que es una mezcla de un alcohol, y una cetona y/o un ester y eliminacion del disolvente.
US20070032665A1 (en) * 2005-08-04 2007-02-08 Srinivasulu Gudipati Preparation of atorvastatin calcium form i

Also Published As

Publication number Publication date
US20020183378A1 (en) 2002-12-05
ES2215495T1 (es) 2004-10-16
US20050261360A1 (en) 2005-11-24
KR20030059297A (ko) 2003-07-07
JP2004514694A (ja) 2004-05-20
ES2437157T3 (es) 2014-01-09
PL363228A1 (en) 2004-11-15
US20060106231A1 (en) 2006-05-18
BR0115892A (pt) 2003-10-28
CA2689915A1 (en) 2002-06-06
US20050004206A1 (en) 2005-01-06
US20050261359A1 (en) 2005-11-24
BG107856A (en) 2004-11-30
HRP20030523A2 (en) 2005-06-30
EP1363621A4 (en) 2005-12-28
AU2002217927A1 (en) 2002-06-11
CA2429590C (en) 2008-06-10
EP2192113A1 (en) 2010-06-02
CN1489463A (zh) 2004-04-14
HUP0600538A3 (en) 2010-09-28
MXPA03004844A (es) 2005-04-19
CA2429590A1 (en) 2002-06-06
EP2194041A1 (en) 2010-06-09
US20050090542A1 (en) 2005-04-28
US20060100267A1 (en) 2006-05-11
IS6829A (is) 2003-05-27
EP1363621A1 (en) 2003-11-26
US7468444B2 (en) 2008-12-23
CA2625277A1 (en) 2002-06-06
KR100765871B1 (ko) 2007-10-11
US20060058533A1 (en) 2006-03-16
US7161012B2 (en) 2007-01-09
JP2009120624A (ja) 2009-06-04
US7189861B2 (en) 2007-03-13
US20050267198A1 (en) 2005-12-01
US20060106232A1 (en) 2006-05-18
NO20032425L (no) 2003-07-25
US7144916B2 (en) 2006-12-05
US20080214650A1 (en) 2008-09-04
IL156055A0 (en) 2003-12-23
NO20032425D0 (no) 2003-05-28
US20060100445A1 (en) 2006-05-11
CZ20031766A3 (cs) 2004-08-18
EP1783113A2 (en) 2007-05-09
HUP0600538A2 (en) 2006-09-28
US6992194B2 (en) 2006-01-31
US20050261361A1 (en) 2005-11-24
US7256212B2 (en) 2007-08-14
SK8062003A3 (en) 2004-07-07
EP1783113A3 (en) 2007-05-30
WO2002043732A1 (en) 2002-06-06
US20060100446A1 (en) 2006-05-11
US7488750B2 (en) 2009-02-10
US7456297B2 (en) 2008-11-25
DE01998348T1 (de) 2004-08-26
US7342120B2 (en) 2008-03-11
US7151183B2 (en) 2006-12-19
YU42803A (sh) 2006-05-25
HRP20130545A2 (hr) 2013-11-08
IL156055A (en) 2010-12-30
EP2192112A1 (en) 2010-06-02
US20050282885A1 (en) 2005-12-22
EP2192112B1 (en) 2013-08-28

Similar Documents

Publication Publication Date Title
TR200400815T3 (tr) AtorvastatinÁyarı@kalsiyumunÁyeniÁkristalÁformlarıÁveÁbunlarınÁhazırlanmasıÁiçinÁişlemlerÁayrıcaÁdiğerÁformlarınÁhazırlanmasıÁiçinÁyeniÁişlemler
MXPA02004666A (es) Gelatinas recombinantes.
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
NO965378D0 (no) Pyrazolo- og pyrolopyridiner
WO2001064835A8 (en) Novel nucleic acids and polypeptides
PT1140944E (pt) Derivados de epotilona e sua utilizacao como agentes antitumorais
BR0214309A (pt) Derivados aril-1,4-pirazina substituìdos
NO20041493L (no) Kjemiske forbindelser.
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
ATE330017T1 (de) Kallikrein gen
BR0306905A (pt) Vacinas de flavivìrus
DE50208918D1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
TR200402030T4 (tr) İkame edilen I-aminobutan-3-ol-türevleri
DE60202669D1 (de) 6-phenylbenzonaphthyidine
DK1204659T3 (da) Serotonerge benzofuraner
ATE383874T1 (de) Perylenequinonen zur anwendung als sonosensitizer
ATE305517T1 (de) Neurotrypsin
SE0302361D0 (sv) Inhibering av upptagning av monoamin
ATE277924T1 (de) Aryl-8-azabicyclo(3.2.1)octanes für die behandlung von depression
DE59803066D1 (de) Substituierte benzyloxyimino-verbindungen
TR200003203T2 (tr) Karboksaldehitin saflaştırılması
TR200401875T2 (tr) Endoparazit öldürücü bileşimler
ATE343390T1 (de) Kalzilytische verbindungen
ES2192034T3 (es) Feniluracilos substituidos con efecto herbicida.
TR200100475T2 (tr) N-İkameli azabisikloheptan türevlerinin üretimleri ve kullanımları.